Mylan announces nationwide EpiPen recall over potential defect

Cheryl Sanders
April 2, 2017

Mylan has also been heavily criticized for classifying EpiPen as a generic rather than a branded product, which led to much smaller rebates from the company to state Medicaid programs. Mylan says certain epinephrine auto-injectors may have a defect that could "make the device hard to activate in an emergency".

Mylan NV said it was expanding a recall of its EpiPen allergy injection to the USA, 10 days after it issued a recall of more than 80,000 devices around the world.

EpiPens are filled with epinephrine, which is injected into a person's thigh to counteract potentially fatal severe allergic reactions.

The recall now covers 13 lots distributed from December 17, 2015 through July 1, 2016. Mylan calls the incidents "extremely rare," but in the case of a life-saving drug that is administered in emergency situations even one defective product is too many.

Replacement EpiPens can be obtained from your pharmacy, if it has the auto-injector (or its generic equivalent) in stock.

The announcement of the recall occurs a few weeks after a first notice of two technical failures outside of Canada was issued.

The injection is used to counteract unsafe allergic reactions, such as those from bee stings or food allergies.

Patients are being directed to for replacement instructions, and the company is encouraging patients to keep their EpiPens handy even if they can't immediately get a replacement. The recalled products were made by Meridian Medical Technologies and distributed by Mylan Specialty.

Anyone who seeks more information regarding this recall can easily visit for instructions and guidelines.

Other reports by iNewsToday